Journal of Hepatology
Volume 51, Issue 4 , Pages 623-625 , October 2009

Cost-effectiveness of oral treatments for chronic hepatitis B

References 

  1. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis. J Hepatol. 2009;51:640–646
  2. Aggarwal R, Ghoshal UC, Naik SR. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India. 2002;15:320–327
  3. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg. 1998;61:238–242
  4. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol. 2002;17:153–164
  5. European Association for The Study of The Liver . EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol. 2009;50:227–242
  6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–2681
  7. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  8. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  9. Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57:84–90
  10. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–352

☆ The author declared that he has served on the advisory boards of Roche, Schering Plough, GlaxoSmithKline, Gilead Sciences, Novartis, Idenix, and Bristol Myers Squibb.

PII: S0168-8278(09)00529-7

doi: 10.1016/j.jhep.2009.07.015

Journal of Hepatology
Volume 51, Issue 4 , Pages 623-625 , October 2009

Article Tools